Key result
Increased pulmonary blood flow impairs lung maturation, uncovering immune, cell-cycle, and circadian targets to prevent maldevelopment.
Why the study?
The impact of increased pulmonary blood flow from congenital heart diseases on postnatal lung maturation was unknown.
Does increased pulmonary blood flow impair postnatal lung maturation in neonatal mice?
Does increased pulmonary blood flow impair postnatal lung maturation in neonatal mice?
Answers are grounded in this paper and cite their sources.
A novel neonatal mouse model of increased pulmonary blood flow demonstrates that hyperactive immunity impairs lung maturation, which can be mitigated by immunosuppression with cyclosporine A.
BACKGROUND: Increased pulmonary blood flow (IPF) from congenital heart diseases causes pediatric pulmonary hypertension and respiratory distress, yet its impact on postnatal lung maturation remains unknown. OBJECTIVES: This study aimed to establish a neonatal model of IPF and elucidate the molecular mechanisms underlying impaired lung maturation, thereby identifying potential therapeutic targets. METHODS: Neonatal mice underwent surgical creation of an aortocaval fistula to induce IPF. Bulk RNA sequencing compared lung transcriptomes at postnatal day (P)14 (alveolar stage) and P30 (maturity) in IPF vs sham-operated controls. Histological validation was performed, and the effects of immunosuppression (cyclosporine A) were assessed. RESULTS: IPF generated 2,272 differentially expressed genes vs 943 in controls, revealing the following: 1) shared downregulation of extracellular matrix organization and cell cycle pathways; 2) IPF-specific cell cycle dysregulation (downregulated Birc5/CENPE) and hyperactive immunity (upregulated NLRP3/IL23R) impairing alveolar/capillary development; 3) suppressed circadian (Per2) and neural pathways (Nr1d1) unique to normal maturation. Cyclosporine A treatment mitigated alveolar simplification, attenuated vascular remodeling, and improved alveolar epithelial differentiation. CONCLUSIONS: This study establishes the first neonatal IPF model and identifies actionable therapeutic targets, including immune modulators (NLRP3/IL23R inhibitors), cell cycle regulators (Birc5/CENPE agonists), and neural/circadian mediators (Nr1d1/Per2 activators). These findings provide a roadmap for mitigating IPF-driven lung maldevelopment.
No takes yet. Share an insight, caveat, or question.
Zheng et al. (2026) studied Increased pulmonary blood flow. Surgical creation of an aortocaval fistula vs. Sham-operated controls was evaluated on Differentially expressed genes. In a neonatal mouse model, increased pulmonary blood flow generated 2,272 differentially expressed genes versus 943 in controls, impairing alveolar development via hyperactive immunity.
Synapse has enriched 10 related papers. Consider them for comparative context: